Abstract: The present invention relates to a use of a natural compound Anisomelic acid extracted from Anisomeles indica O. Kuntze in the preparation of pharmaceutical compositions for inhibiting the infection and replication of novel coronaviruses and the mutant strains (SARS-CoV-2 variants) thereof, the Anisomelic acid is a compound comprising a chemical structural Formula I, the pharmaceutical composition includes a safe and effective amount of Anisomelic acid, that is, the pharmaceutical composition is a combination of a safe and effective amount of Anisomelic acid and its pharmaceutically acceptable salt or carrier thereof.

Abstract: A method for asymmetric synthesis of (?)-Anisomelic Acid is provided in the present invention, a chiral compound (?)-Costunolide is used as a starting material, a key intermediate is obtained by a regioselective ozone decomposition reaction, then carbon chain extension is performed by a Horner-Wadsworth-Emmons (HWE) reaction and a Peterson olefination reaction, and a (?)-anisomelic acid fourteen-membered carbocyclic skeleton is constructed by a ring-closing metathesis (RCM) reaction, laying an important foundation for subsequent (?)-anisomelic acid biological activity research, in the synthesis route, various (?)-anisomelic acid analogs can also be obtained from the key intermediate, the reaction operations in the synthesis route are simple and the present invention can be widely popularized and used.

Abstract: The present invention relates to a composition for treating respiratory diseases due to particulate matter, wherein the composition contains, as active ingredients, essential oil extracts of mint, Asarum sieboldi, and fir leaves. A composite obtained by mixing essential oil extracts of mint, Asarum sieboldi, and fir leaves according to the present invention exhibits the effect of relieving the symptoms of chronic respiratory diseases caused by ovalbumin and particulate matter in an animal model, and thus can be effectively used to directly treat respiratory diseases due to particulate matter.

Abstract: A compound of Formula I compound—Ovatodiolide which is safe and effective to use in a pharmaceutical composition for inhibition of SARS-CoV-2 is provided. The pharmaceutical composition comprising a safe and effective amount of a compound of Formula I compound—Ovatodiolide or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, which has great potential to treat SARS-CoV-2 induced COVID-19 based on a safe and effective amount of a compound of Formula I compound—Ovatodiolide.

Abstract: The present invention is directed to a method for inhibiting growth of ovarian cancer cells in a subject in need thereof, comprising administering to said subject a composition comprising an effective amount of 4-acetyl-antroquinonol B or a pharmaceutical acceptable salt thereof, and a pharmaceutically acceptable carrier.

Abstract: This invention provides a method for inhibiting tumor growth caused by cancer stem cells in a subject in need thereof, which comprises administering to the subject an effective amount of 4-acetyl-antroquinonol B.

Abstract: The present invention provides a method for preparing antrocin of pharmaceutically acceptable salts thereof via a series of gold-catalyzed cyclization to construct the (6-6-5) tricyclic core frame. The present invention also provides a use of a composition in preparing drugs for suppressing growth of non-small cell lung cancer cells, wherein the composition comprises an effective amount of antrocin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a method for preparing antrocin of pharmaceutically acceptable salts thereof via a series of gold-catalyzed cyclization to construct the (6-6-5) tricyclic core frame. The present invention also provides a use of a composition in preparing drugs for suppressing growth of non-small cell lung cancer cells, wherein the composition comprises an effective amount of antrocin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier.

Abstract: The present invention relates to a process of preparation of optically active antrocin. At first, to introduce the correct configuration of trans-decalone, alkyl aluminum/TMSCN was used to react with decalenone. The resulting racemic nitrile-decalone was resolved with chiral diol by ketalization to produce two chromatography separable diasteromers. After a simple column chromatography, optically pure compounds were obtained. Formylation was a critical step for the lactone formation. The rest of the synthesis is straight forward through oxidation and olefination. Accordingly, the total synthesis was completed in 10 steps with 7% overall yield from commercially available 6-methoxy-2-tetralone.

Abstract: This subject invention is directed to a method for inhibition of cancer cells, comprising administrating an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, wherein the cancer cells are selected from colorectal cancer cells, liver cancer cells, lung cancer cells or breast cancer cells.

Abstract: The present invention relates to a process of preparation of optically active antrocin. At first, to introduce the correct configuration of trans-decalone, alkyl aluminum/TMSCN was used to react with decalenone. The resulting racemic nitrile-decalone was resolved with chiral diol by ketalization to produce two chromatography separable diasteromers. After a simple column chromatography, optically pure compounds were obtained. Formylation was a critical step for the lactone formation. The rest of the synthesis is straight forward through oxidation and olefination. Accordingly, the total synthesis was completed in 10 steps with 7% overall yield from commercially available 6-methoxy-2-tetralone.

Abstract: This subject invention is directed to a method for inhibition of cancer cells, comprising administrating an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, wherein the cancer cells are selected from colorectal cancer cells, liver cancer cells, lung cancer cells or breast cancer cells.

Abstract: This subject invention is directed to a pharmaceutical composition for the inhibition of cancer cells, comprising an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier.

Abstract: The invention discloses a two-step process for recovery of thuringiensin, comprising adsorbing the thuringiensin from fermentation broth by calcium silicate, and dissociating the thuringiensin by dibasic sodium phosphate. The resulting thuringiensin can be further purified by using semi-preparative HPLC and electrodialysis to remove the excess salts from the recovered thuringiensin solution.

Abstract: Quantitative analysis for thuringiensin by capillary electrophoresis (“CE’) was demonstrated. CE is a suitable separation technique for thuringiensin because of its high resolution, great efficiency, rapid analysis and small consumption of sample. Tryptophan, an aromatic amino acid sharing a similar UV absorptive spectrum as thuringiensin, was used as an internal standard to avoid some inaccurate results caused by the questionable stability of purified thuringiensin. A mixed amount of tryptophan was mixed with varied amount of newly made thuringiensin standards for CE analysis. The electropherograms showed that the peak of tryptophan appeared around 8 minutes, which is 6 minutes earlier than the peak of thuringiensin. The peak area ratio between thuringiensin and tryptophan is proportional to the amount of thuringiensin in the mixture. The linear regression has been established to assess the peak area ratio that can be used to quantify the concentration of thuringiensin.

Abstract: A process of treating meal containing vegetable proteins is disclosed. This process includes the step of extracting the metal with a suitable aqueous solvent in which the vegetable proteins are soluble to obtain an extraction solution. The solubility of the dissolved protein in the extraction solution is then adjusted to precipitate at least some of the protein and therefore obtain a precipitated protein fraction and an unprecipitated protein fraction in solution. The precipitated protein fraction is then separated from the protein fraction in solution, and the unprecipitated protein fraction is separated from the undesirable components in the solution by membrane processing. Each of the protein fractions is then suitably dried to recover the proteins.